Chronotherapeutic Ocular Delivery System Comprising a Combination of Prostaglandin and a Beta-Blocker for Treating Primary Glaucoma
First Claim
1. A delivery system incorporating pharmaceutical products for delivery to an eye in the treatment of primary open-angle glaucoma (POAG), comprising:
- (a) a biocompatible erodible material incorporating a therapeutically-effective amount of a prostaglandin analogue, and(b) a reservoir containing a therapeutically-effective amount of a beta-blocker,whereby, when the delivery system is placed in the eye the prostaglandin analogue is delivered gradually as the erodible material is eroded, and the beta-blocker is delivered rapidly when at least a predetermined portion of the erodible material has been eroded.
1 Assignment
0 Petitions
Accused Products
Abstract
Chronotherapeutic delivery system for treating primary open-angle glaucoma, comprising a delivery system incorporating pharmaceutical products for delivery to an eye in the treatment of primary open-angle glaucoma (POAG), comprising: (a) a biocompatible erodible material incorporating a therapeutically-effective amount of a prostaglandin analogue, and (b) a reservoir containing a therapeutically-effective amount of a beta-blocker, whereby, when the delivery system is placed in the eye the prostaglandin analogue is delivered gradually as the erodible material is eroded, and the beta-blocker is delivered rapidly when at least a predetermined portion of the erodible material has been eroded.
36 Citations
21 Claims
-
1. A delivery system incorporating pharmaceutical products for delivery to an eye in the treatment of primary open-angle glaucoma (POAG), comprising:
-
(a) a biocompatible erodible material incorporating a therapeutically-effective amount of a prostaglandin analogue, and (b) a reservoir containing a therapeutically-effective amount of a beta-blocker, whereby, when the delivery system is placed in the eye the prostaglandin analogue is delivered gradually as the erodible material is eroded, and the beta-blocker is delivered rapidly when at least a predetermined portion of the erodible material has been eroded. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 21)
-
-
17. A delivery system incorporating pharmaceutical products for delivery to an eye in the treatment of primary open-angle glaucoma (POAG), comprising:
-
(a) a layer of PEO incorporating a therapeutically-effective amount of latanoprost; (b) a layer of PVA containing a therapeutically-effective amount of betaxolol; (c) a layer of PLGA separating the PEO and PVA layers; (d) a polypropylene insulating support located on the side surface(s) of the PVA layer; (e) a barrier layer of PLGA or polypropylene located on the lower surface of the reservoir containing the betaxolol while the layer of PEO incorporating the latanoprost is located on the upper surface of the layer of PVA, or vice versa; (f) a polyacrylic acid mucoadhesive polymer, whereby, when the delivery system is placed in the eye the latanoprost is delivered gradually as the PEO is eroded, and the betaxolol is delivered rapidly when at least a predetermined portion of the PEO has been eroded.
-
-
19. (canceled)
Specification